MYC and neoplasm: For example, Omomyc has been shown to antagonize c-MYC–mediated transcriptional activity and induce sustained tumor regression across multiple tumor models, becoming the first MYC inhibitor to enter clinical trials in patients with advanced solid tumors—providing proof of concept that MYC inhibition is a viable anticancer strategy [70].